文献速递免疫规划

卡介苗复种对乌干达城市青少年无关疫苗免疫应答的影响(POPVAC C):一项开放标签随机对照试验

The effect of BCG revaccination on the response to unrelated vaccines in urban Ugandan adolescents (POPVAC C): an open-label, randomised controlled trial.
PubMed 文献 · Lancet Glob Health · 2024-01-01

在乌干达城市青少年中开展的开放标签随机对照试验,比较卡介苗复种与不复种对后续无关疫苗免疫原性的影响。共纳入300名13-17岁参与者,复种组151例、对照组149例。结果显示复种对黄热病、伤寒、HPV及破伤风-白喉疫苗的抗体应答均无显著影响,两组均无严重不良事件。

要点

  • 卡介苗复种对黄热病中和抗体滴度无显著影响,GMR 0.95(95%CI 0.75-1.19;p=0.62)。
  • 复种对伤寒O:LPS特异性IgG、HPV-16/18 IgG及破伤风-白喉类毒素IgG均无显著影响。
  • 两组均未报告严重不良事件。

核心结论

  • 本研究未发现卡介苗复种能有效改善该低收入城市环境中其他疫苗免疫原性的证据。

研究设计与样本

  • 开放标签随机对照试验,在乌干达城市出生队列研究的13-17岁青少年中比较卡介苗复种与不复种对后续无关疫苗免疫原性的影响。
  • 共筛查376人,纳入并随机分配300人(复种组151例[50%],不复种组149例[50%]),178例(59%)为男性、122例(41%)为女性。
  • 复种组于第0周接受皮内卡介苗-Russia疫苗0.1 mL;所有参与者于第4周接受黄热病疫苗、口服伤寒疫苗和四价HPV疫苗,于第28周接受破伤风-白喉类毒素疫苗和HPV加强针。

主要发现

  • 黄热病PRNT50滴度GMR为0.95(95%CI 0.75-1.19;p=0.62),PRNT90滴度GMR为0.94(95%CI 0.74-1.19;p=0.60)。
  • 伤寒O:LPS特异性IgG的GMR为0.99(95%CI 0.80-1.23;p=0.94)。
  • HPV-16 IgG的GMR为0.97(95%CI 0.69-1.35;p=0.85),HPV-18 IgG的GMR为1.03(95%CI 0.76-1.40;p=0.83)。
  • 破伤风类毒素特异性IgG的GMR为1.13(95%CI 0.87-1.47;p=0.36),白喉为1.00(95%CI 0.87-1.16;p=0.97)。
  • 两组均无严重不良事件;复种组151例中142例(91%)完成随访,不复种组149例中139例(93%)完成随访。

关键数值与推荐

  • 主要结局为黄热病疫苗接种后4周中和抗体滴度、Ty21a疫苗接种后4周伤寒O:LPS特异性IgG浓度、HPV疫苗接种后4周HPV-16和HPV-18 L1蛋白特异性IgG浓度。
  • 采用意向性治疗分析,比较组间对数转换后的结局,结果反向转换为几何平均比(GMR)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Immune responses induced by several important vaccines differ between populations, with reduced responses in low-income and rural settings compared with high-income and urban settings. BCG immunisation boosts immune responses to some unrelated vaccines in high-income populations. We aimed to test the hypothesis that BCG revaccination can enhance responses to unrelated vaccines in Ugandan schoolchildren. METHODS: We conducted an open-label, randomised controlled trial to compare the effects of BCG revaccination versus no BCG revaccination on the immunogenicity of subsequent unrelated vaccines among adolescents aged 13-17 years who are participants in an urban Ugandan birth cohort study, in which BCG vaccination was documented at birth. Participants were excluded if they had received any of the trial vaccines or related agents when aged 5 years or older. Computer-generated 1:1 randomisation was implemented in REDCap. Participants were excluded if they were concurrently enrolled in other trials; had a clinically significant history of immunodeficiency, or serious psychiatric conditions or moderate to severe acute illnesses; were taking immunosuppressive medications; had allergies to vaccine components, a predisposition towards developing keloid scarring; positive HIV tests or pregnancy tests; were female participants who were lactating; or if they planned to use investigational drugs, vaccines, blood products, or any combination thereof. Trial participants assigned to the BCG revaccination group received the live parenteral BCG-Russia vaccine (Serum Institute of India, Pune, India; 0·1 mL intradermally, right upper arm) at week 0. All participants received yellow fever vaccine (YF-17D; Sanofi Pasteur, Lyon, France; 0·5 mL intramuscularly, left upper arm), live oral typhoid vaccine (Ty21a; PaxVax, London, UK; one capsule per day taken for three alternate days), and quadrivalent virus-like particle human papillomavirus (HPV) vaccine (Merck, Rahway, NJ, USA; 0·5 mL intramuscularly, left upper arm) at week 4; and toxoid vaccines (tetanus-diphtheria; Serum Institute of India; 0·5 mL intramuscularly, left upper arm) and an HPV booster at week 28. An additional HPV vaccination at week 8 was provided to female participants older than 14 years who had not previously been vaccinated. The primary outcomes were yellow fever neutralising antibody titres at 4 weeks post-YF-17D vaccination, Salmonella enterica serovar Typhi (henceforth S Typhi) O-lipopolysaccharide (O:LPS)-specific IgG concentration at 4 weeks post-Ty21a vaccination, and HPV-16 and HPV-18 L1 protein-specific IgG concentration at 4 weeks post-HPV vaccination. Primary outcome assays were conducted at week 8, and at week 52 for tetanus-diphtheria. We conducted an intention-to-treat analysis comparing log-transformed outcomes between trial groups, with results back-transformed to geometric mean ratios (GMRs). The safety population comprised all randomly allocated participants. The trial was registered at the ISRCTN Registry (ISRCTN10482904) and is complete. FINDINGS: Between Aug 31 and Oct 12, 2020, we screened 376 potential participants for eligibility. We enrolled and randomly allocated 300 participants to the two groups (151 [50%] to the BCG group and 149 [50%] to the no BCG group). 178 (59%) of 300 participants were male and 122 (41%) were female. 142 (91%) of 151 participants in the BCG group and 139 (93%) of 149 in the no BCG group completed follow-up. There was no effect of BCG revaccination, compared with no BCG revaccination, on the response observed for any vaccine. Yellow fever plaque reduction neutralising reference tests (PRNT50) titres (the reciprocal of the last plasma dilution that reduced by 50%) had a GMR of 0·95 (95% CI 0·75-1·19; p=0·62) and PRNT90 (reciprocal of the last plasma dilution that reduced by 90%) had a GMR of 0·94 (0·74-1·19; p=0·60); IgG to S Typhi O:LPS was 0·99 (0·80-1·23; p=0·94); IgG to HPV-16 was 0·97 (0·69-1·35; p=0·85) and to HPV-18 was 1·03 (0·76-1·40; p=0·83); and toxoid-specific IgG for tetanus was 1·13 (0·87-1·47; p=0·36) and was 1·00 (0·87-1·16; p=0·97) for diphtheria. There were no serious adverse events in either group. INTERPRETATION: We found no evidence that BCG revaccination is an effective strategy to improve immunogenicity of other vaccines in this low-income, urban setting. FUNDING: UK Medical Research Council. TRANSLATION: For the Luganda translation of the abstract see Supplementary Materials section.

来源:Lancet Glob Health,查看原文。版权归原作者所有。

引用

  1. Nassuuna J, Zirimenya L, Nkurunungi G, et al. The effect of BCG revaccination on the response to unrelated vaccines in urban Ugandan adolescents (POPVAC C): an open-label, randomised controlled trial. Lancet Glob Health. 2024. PMID: 39424573. doi:10.1016/S2214-109X(24)00282-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。